

Vet Biotechnology

Vet Biotechnology Ltd (ACN 105 577 017)
(NSX codes VBL, VBLO)

November 18, 2006 at 04.30 EST.

Board changes at Vet Biotechnology

The directors of Vet Biotechnology Ltd are pleased to announce the appointment of Alan Preston Beasley as a director of the company.

Alan is a director of QX21 Health Ltd and is the Managing Director of Ascend Asset Management Ltd.

He was Managing Director of BNP Paribas Asset Management (Australia) Limited where his role included Chief Investment Officer and Head of Asset Allocation.

Alan previously held the position of Company Secretary, Associate Director of Bankers Trust Australia including Vice President for the BTA Retirement Fund

Alan has a Bachelor of Economics majoring in economics and accounting. He is a Certified Practising Accountant, Fellow of the Chartered Institute of Company Secretaries and Administrators, and a Fellow of the Australian Institute of Company Directors. He has also attended Stanford University where he completed the International Investment Management Program.

Both Paul Lawrence Kerr and Paul Andrew Mariani have announced their resignation as directors to pursue their own commercial interests. Both have made a significant contribution to the company and the directors thank them for their time and effort.

Vet Biotechnology is listed on the Newcastle Stock Exchange (NSX codes VBL, VBLO).

For further information, contact:

Mr Peter Le Messurier
Chairman
Vet Biotechnology Ltd
ACN 105 577 017

Vet Biotechnology Ltd
Suite 7, 114 Rundle Street
Kent Town, South Australia 5067
Telephone: 61 8 8363 1159
Facsimile: 61 8 8362 2598

Web page: www.vetbiotechnology.com.au

Ends...